PDE11A
ENSG00000128655
Target class
Enzyme
Chromosome
2
- Chemical probe available
- No
- Target name
- PDE11A
- Gene name
- Phosphodiesterase 11A
- Gene symbol
- PDE11A
- Protein name
- Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (EC 3.1.4.35) (EC 3.1.4.53) (cAMP and cGMP phosphodiesterase 11A)
- Gene biotype
- Protein coding
- Gene family
- Phosphodiesterases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 9
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 4.57
- Tissue specificity (Gini)
- 0.623
- Tissue specificity (tau)
- 0.902
- KEGG gene identifiers
- hsa:50940
- Protein interaction confidence
- 0.8044
- Protein interaction partners
- 37
- R-HSA-418457
- R-HSA-418555
- End position
- 178108339
- Start position
- 177623244
- Chromosome
- 2
- Strand
- Reverse
- Cytoplasm, cytosol .
- Cytosol
- Microtubules
Publication evidence
- PubMed 10906126
- Tissue specificity (tau)
- 0.901779
- Expression inequality (Gini)
- 0.622525
Expression in transcripts per million
- Prostate
- 4.57
- Brain - Spinal cord (cervical c-1)
- 2.99
- Testis
- 1.75
- Pituitary
- 1.57
- Muscle - Skeletal
- 1.52
Expression in transcripts per million
- Prostate4.57
- Brain - Spinal cord (cervical c-1)2.99
- Testis1.75
- Pituitary1.57
- Muscle - Skeletal1.52
- Liver1.43
- Cervix - Endocervix1.24
- Brain - Substantia nigra1.21
- Thyroid1.1
- Brain - Hypothalamus0.91
- Cervix - Ectocervix0.78
- Breast - Mammary Tissue0.62
- Pancreas0.59
- Minor Salivary Gland0.52
- Brain - Hippocampus0.48
- Colon - Sigmoid0.44
- Brain - Amygdala0.44
- Uterus0.42
- Brain - Caudate (basal ganglia)0.37
- Kidney - Medulla0.36
- Brain - Putamen (basal ganglia)0.35
- Brain - Anterior cingulate cortex (BA24)0.33
- Kidney - Cortex0.31
- Brain - Nucleus accumbens (basal ganglia)0.3
- Colon - Transverse0.29
And 29 more, listed on the interactive page.
Biological processes
- GO:0007165
Cellular components
- GO:0005829
- GO:0004114
- GO:0004115
- GO:0004118
- GO:0030553
- GO:0047555
Related records
Trials (239)
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Bioavailability Study of LY2452473 and Tadalafil
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
- A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
- A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
- A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
- A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
- A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
- A Single Dose Randomized Five-Way Crossover Pharmacokinetics (PK) Study of Tadalafil Semi-Chewable (Gummy) Formulations in Healthy Volunteers
- A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
- A Study in Benign Prostatic Hyperplasia
- A Study in Erectile Dysfunction
- A Study in Erectile Dysfunction
- A Study in Patients With Erectile Dysfunction
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
- A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants
- A Study of LY2623091 in Healthy Participants
- A Study of LY2623091 in Participants With High Blood Pressure